Form 4 for AMRX Amneal Pharmaceuticals, Inc.
Accepted 2023-03-07 00:00:00 ET · period of report 2023-03-03 · accession 0001209191-23-016935 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-07 | 2023-03-03 | AMRX | Daly Jason B. | SVP, CLO | F - Tax | $1.92 | -8,164 | 14.5K | -36% | -$15.7K |
| D | 2023-03-07 | 2023-03-03 | AMRX | Daly Jason B. | SVP, CLO | M - OptEx | — | +22.6K | 22.6K | New | — |
| D | 2023-03-07 | 2023-03-03 | AMRX | Daly Jason B. | SVP, CLO | M - OptEx | $0.00 | -22.6K | 67.9K | -25% | $0 |
| DM | 2023-03-07 | 2023-03-03 | AMRX | Daly Jason B. | SVP, CLO | A - Grant | $0.00 | +458.7K | 305.8K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2023-03-03 | F | D | 8,164 | $1.92 | 14,481 | D | — | — | (F3) Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| 2 | Common | Class A Common Stock | 2023-03-03 | M | A | 22,645 | — | 22,645 | D | — | — | (F1) Represents the gross number of shares of common stock issuable to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |
| 3 | Derivative | Restricted Stock Units | 2023-03-03 | M | D | 22,645 | $0.00 | 67,935 | D | — · — to — | 22,645 Class A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. (F4) On March 3, 2022, the reporting person was granted 90,580 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. |
| 4 | Derivative | Restricted Stock Units | 2023-03-03 | A | A | 152,905 | $0.00 | 152,905 | D | — · — to — | 152,905 Class A Common Stock | (F2) Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. (F5) The restricted stock units vest in four equal annual installments beginning on March 3, 2024. |
| 5 | Derivative | Performance-Based Restricted Stock Units | 2023-03-03 | A | A | 305,810 | $0.00 | 305,810 | D | — · — to — | 305,810 Class A Common Stock | (F7) Represents a performance-based restricted stock unit grant of 152,905 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. (F6) Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. |